↓ Skip to main content

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, December 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
1 tweeter

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
72 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
Published in
Alzheimer's Research & Therapy, December 2016
DOI 10.1186/s13195-016-0220-z
Pubmed ID
Authors

Panagiotis Alexopoulos, Lukas Werle, Jennifer Roesler, Nathalie Thierjung, Lena Sophie Gleixner, Igor Yakushev, Nikolaos Laskaris, Stefan Wagenpfeil, Philippos Gourzis, Alexander Kurz, Robert Perneczky

Abstract

According to new diagnostic guidelines for Alzheimer's disease (AD), biomarkers enable estimation of the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD dementia for patients with mild cognitive impairment (MCI). Nonetheless, how conflicting biomarker constellations affect the progression risk is still elusive. The present study explored the impact of different cerebrospinal fluid (CSF) biomarker constellations on the progression risk of MCI patients. A multicentre cohort of 469 patients with MCI and available CSF biomarker results and clinical follow-up data was considered. Biomarker values were categorized as positive for AD, negative or borderline. Progression risk differences between patients with different constellations of total Tau (t-Tau), phosphorylated Tau at threonine 181 (p-Tau) and amyloid-beta 1-42 (Aβ42) were studied. Group comparison analyses and Cox regression models were employed. Patients with all biomarkers positive for AD (N = 145) had the highest hazard for progression to dementia due to AD, whilst patients with no positive biomarkers (N = 111) had the lowest. The risk of patients with only abnormal p-Tau and/or t-Tau (N = 49) or with positive Aβ42 in combination with positive t-Tau or p-Tau (N = 119) is significantly lower than that of patients with all biomarkers positive. The risk of progression to dementia due to AD differs between patients with different CSF biomarker constellations.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 72 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 17%
Other 9 13%
Researcher 9 13%
Student > Master 6 8%
Student > Bachelor 5 7%
Other 13 18%
Unknown 18 25%
Readers by discipline Count As %
Medicine and Dentistry 19 26%
Neuroscience 12 17%
Psychology 4 6%
Biochemistry, Genetics and Molecular Biology 3 4%
Environmental Science 2 3%
Other 8 11%
Unknown 24 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 October 2017.
All research outputs
#1,919,305
of 19,645,988 outputs
Outputs from Alzheimer's Research & Therapy
#420
of 1,017 outputs
Outputs of similar age
#50,904
of 410,029 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#22
of 58 outputs
Altmetric has tracked 19,645,988 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,017 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.3. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 410,029 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.